Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on April 24, 2023. The report details a corporate action taken on the same date regarding the Company's capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company effected a one-for-45 reverse stock split of its issued and outstanding common stock at 12:01 a.m. Eastern Time on April 24, 2023.
- Share Conversion: Every 45 shares of Common Stock were converted into one share. No fractional shares were issued; shareholders entitled to a fractional share received one whole share instead.
- Trading Status: Common Stock began trading on the NYSE American on a reverse stock split-adjusted basis on April 25, 2023.
- Security Adjustments: All outstanding securities, including stock options, warrants, and Series A preferred stock, were adjusted in accordance with their terms.
- CUSIP Change: The CUSIP number for the Common Stock changed to 12482W 309.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the standard disclosure that the description of the Articles of Amendment is a summary and qualified by reference to the full text filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the new CUSIP number (12482W 309) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Review the adjustment terms for any outstanding stock options or warrants held.
- Check the trading price on NYSE American starting April 25, 2023, to ensure it reflects the 45:1 split ratio.